Abstract
ObjectiveMelanoma is rare but dangerous skin cancer, and it can spread rather quickly in the advanced stages of the tumor. Abundant evidence suggests the relationship between tumor development and progression and the immune system. A robust gene risk model could provide an accurate prediction of clinical outcomes. The present study aimed to explore a robust signature of immune-related gene pairs (IRGPs) for estimating overall survival (OS) in malignant melanoma.MethodsClinical and genetic data of skin cutaneous melanoma (SKCM) patients from The Cancer Genome Atlas (TCGA) was performed as a training dataset to identify candidate IRGPs for the prognosis of melanoma. Two independent datasets from the Gene Expression Omnibus (GEO) database (GSE65904) and TCGA dataset (TCGA-UVM) were selected for external validation. Univariate and multivariate Cox regression analyses were then performed to explore the prognostic power of the IRGPs signature and other clinical factors. CIBERSORTx was applied to estimate the fractions of infiltrated immune cells in bulk tumor tissues.ResultsA signature consisted of 33 IRGPs was established which was significantly associated with patients’ survival in the TCGA-SKCM dataset (P = 2.0×10−16, Hazard Ratio (HR) = 4.220 (2.909 to 6.122)). We found the IRGPs signature exhibited an independent prognostic factor in all the three independent cohorts in both the univariate and multivariate Cox analysis (P<0.01). The prognostic efficacy of the signature remained unaffected regardless of whether BRAF or NRAS was mutated. As expected, the results were verified in the GSE65904 dataset and the TCGA-UVM dataset. We found an apparent shorter OS in patients of the high-risk group in the GSE65904 dataset (P = 2.1×10−3; HR = 1.988 (1.309 to 3.020)). The trend in the results of the survival analysis in TCGA-UVM was as we expected, but the result was not statistically significant (P = 0.117, HR = 4.263 (1.407 to 12.91)). CD8 T cells, activated dendritic cells (DCs), regulatory T cells (Tregs), and activated CD4 memory T cells presented a significantly lower fraction in the high-risk group in the TCGA-SKCM dataset(P <0.01).ConclusionThe results of the present study support the IRGPs signature as a promising marker for prognosis prediction in melanoma.
Highlights
Melanoma is a kind of malignant tumor that originates from melanocytes [1]
A signature consisted of 33 immune-related gene pairs (IRGPs) was established which was significantly associated with patients’ survival in the The Cancer Genome Atlas (TCGA)-skin cutaneous melanoma (SKCM) dataset (P = 2.0×10−16, Hazard Ratio (HR) = 4.220 (2.909 to 6.122))
We found the IRGPs signature exhibited an independent prognostic factor in all the three independent cohorts in both the univariate and multivariate Cox analysis (P
Summary
Melanoma is a kind of malignant tumor that originates from melanocytes [1]. If not found and treated at an early stage, melanoma may rapidly spread to other organs of the whole body, which may lead to approximately 10,000 deaths in the USA each year [2]. Primary tumors are more commonly located in the lower extremities. For primary malignant melanoma that has not metastasized early, surgical resection is the most effective method, and more than 90% of patients have more than five years of survival [3]. For patients with more extensive melanoma, neighboring lymph nodes will be examined to determine whether metastasis has occurred. The degree of improvement in radiotherapy and chemotherapy is minimal, so the mortality rate is very high in advanced melanoma [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
